← All trials
NCT01264328
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2010
- Primary completion
- Oct 1, 2011
- Completion date
- Oct 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Grupo Español de Tratamiento de Tumores de Cabeza y CuelloLead sponsor
- Fundación Hospital AlcorcónOverall official - principal investigator
- University of GranadaOverall official - principal investigator
- University of ValenciaOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- AmgenCollaborator
- Trial Form Support S.L.Collaborator
- Clinica Universidad de NavarraOverall official - principal investigator
- University of ZaragozaOverall official - principal investigator
- University of SalamancaStudy director
- University of BarcelonaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.